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Abstract
Self-emulsifying drug delivery systems (SEDDS) have been mainly inves-
tigated to enhance the oral bioavailability of drugs belonging to class II of the 
Biopharmaceutics Classification System. However, in the past few years, they have 
shown promising outcomes in the oral delivery of various types of therapeutic 
agents. In this chapter, we discuss the recent progress in the application of SEDDS 
for oral delivery of protein therapeutics and genetic materials. The role of SEDDS 
in enhancing the oral bioavailability of P-glycoprotein and cytochrome P450 3A4 
substrate drugs is also highlighted. Also, we discuss the most critical evaluation 
criteria of SEDDS. Additionally, we summarize various solidification techniques 
employed to transform liquid SEDDS to the more stable solid self-emulsifying drug 
delivery systems (s-SEDDS) that are associated with high patient compliance. This 
chapter provides a comprehensive approach to develop high utility SEDDS and their 
further transformation into s-SEDDS.
Keywords: solid self-emulsifying drug delivery systems, solidification techniques, 
oral delivery, P-glycoprotein (P-gp), cytochrome P450 3A4 (CYP3A4),  
multidrug resistance (MDR), protein therapeutics, plasmid DNA (pDNA)
1. Introduction
Lipid-based drug delivery systems (LBDDs) have been intensively investi-
gated to overcome various obstacles encountered in oral drug delivery including 
poor aqueous solubility, limited permeability, low therapeutic window, first pass 
metabolism as well as inter- and intraindividual variability in drug response [1]. 
Lipid-based nanoparticles can achieve high loading capacity of hydrophilic and 
hydrophobic drugs [2]. The delivery features of these drug delivery systems could 
be tailored to achieve either immediate or sustained release properties depending 
on the appropriate selection of lipid composition. Most of lipids employed in the 
formulation are generally recognized as safe (GRAS), biocompatible and biode-
gradable [3]. LBDDs can enhance both transcellular and paracellular transport of 
drugs by transient disruption of lipid bilayer cells and alteration of tight junction 
by products of lipid digestion, respectively. Interestingly, they could permeate 
challenging physiological barriers such as blood brain barrier without surface 
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modification due to their lipophilic nature [4]. Further, they are promising carri-
ers for protection of therapeutic peptides against harsh GI environment [3]. Ease 
of preparation, cost effectiveness and possibility of large-scale production make 
LBDDs more attractive compared to polymeric nanoparticulate delivery systems [5].
2. Classification of lipid carriers
Lipid carriers can be classified into various categories depending mainly on 
their method of preparation as well as their physicochemical properties. They 
include liposomes, niosomes, solid lipid nanoparticles (SLNs), nanostructured lipid 
carriers (NLCs), micro and nanoemulsions, self-emulsifying drug delivery systems 
(SEDDS), and lipid-drug conjugates [2, 4].
Liposomes are uni- or multilamellar spherical vesicles which are composed of 
cholesterol and other natural or synthetic phospholipids enfolding an aqueous com-
partment [6]. They were first introduced by Bangham et al. in 1965 [7]. Thus, lipo-
somes have been considered as biocompatible and biodegradable carriers that possess 
efficient delivering capability of hydrophilic and hydrophobic drugs. Advantages of 
liposome-based drug delivery systems include reduction of systemic and of target 
toxicities as well as targeting potential to achieve the desired outcome [8]. Thus, many 
liposome formulations have been approved for commercial use such Ambisome® 
(amphotericin B), Depocyt® (cytarabine), DepoDur® (morphine sulfate) and many 
others. However, their poor stability and rapid elimination by reticuloendothelial 
system limit the widespread applicability of liposomal formulations [4].
Niosomes are first described by Handjani-Vila et al. in 1979 [9]. They are 
nonionic surfactant-based vesicles in which the hydrophilic surfactant heads are 
oriented toward the exterior and the interior of the bilayer while, the hydrophobic 
tails are enclosed inside the bilayer. Therefore, like liposomes, niosomes have the 
ability to encapsulate hydrophilic or lipophilic molecules [10]. Niosomes also have 
cholesterol in their structure which enhances the rigidity of bilayer and reduces 
premature drug release [11]. Niosomes are superior carriers to liposomes in terms of 
production cost, chemical and physical stability, and loading capacity [12].
SLNs and NLCs are the most widely described solid-core lipid-based nanocar-
riers in the scientific literature [3]. SLNs were first described in 1991 to replace the 
liquid oil of O/W emulsions by a single solid lipid or mixture of solid lipids [2]. 
SLNs are composed of either solid lipid or mixture of lipids, that do not melt at 
room or physiological temperature, in an aqueous dispersion stabilized with the 
help of nonionic surfactants [3].SLNs offer the advantage of avoiding the use of 
organic solvents during preparation, effective delivery of both hydrophilic and 
lipophilic drugs, feasibility of surface functionalization with specific moieties to 
enhance their targeting potential, possibility of extended or controlled drug release, 
long shelf-life, biocompatibility, lower acute or chronic toxicity and effective large-
scale production [2, 13, 14]. On the other hand, efficient drug delivery by SLNs is 
challenged by low drug loading capacity due to lipid crystalline nature, expulsion 
of loaded drug due to perfect crystalline lattice formation of the lipid and erratic 
gelation tendency that results in particle aggregation during storage [4, 14].
NLCs were developed to overcome the problem of drug expulsion during phase 
transition or crystallization of lipids comprising SLNs [15]. They also exist as a solid 
lipid matrix at temperature up to about 40°C. However, they are composed of solid 
lipid mixed with an oil which in turn reduces the lipid crystallization capacity and 
enhances the drug loading efficiency [16].
Nanoemulsions are kinetically stable heterogeneous systems composed of ultra-
fine oil droplets dispersed in aqueous media and stabilized by the aid of surfactants 
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and cosurfactants. Nanoemulsions have gained increasing attention as promising 
drug delivery systems due to their multiple advantages including high surface area 
for drug absorption, biocompatibility, increasing drug solubility and improving 
mucosal permeability. Further, many FDA approved nanoemulsion-based products 
of water insoluble drugs are now available for clinical use including Restasis®, 
Estrasorb® and Flexogan®. Microemulsions also offer favorable characteristics 
such as thermodynamic stability, ease of production being formed spontaneously 
without the need for high energy input and high penetration due to the large surface 
area of internal phase [17].
Lipid-drug conjugates (LDCs) are lipid nanoparticle formulations which are 
characterized by the conjugation ability of the lipid matrix with the hydrophilic 
drug moieties, and thus provide novel pro-drugs to achieve many therapeutic out-
comes in oral drug delivery [18]. Like other lipid-based nanocarrier systems, LDCs 
possess several advantages including biocompatibility, being solid at body and room 
temperature, high capacity for loading hydrophilic drugs, high permeation through 
GI tract, enhanced drug absorption through lymphatic uptake, improving stability 
and bioavailability loaded drugs, and feasibility of large scale production [19].
3. Self-emulsifying drug delivery systems
Self-emulsifying drug delivery systems (SEDDS) are lipid-based formulations that 
encompass isotropic mixtures of natural or synthetic oils, solid or liquid surfactants 
and co-surfactants [20]. When they are exposed to aqueous media (e.g., gastroin-
testinal fluids), they undergo self-emulsification to form O/W nanoemulsions or 
microemulsions with a mean droplet size between 20 and 200 nm [21]. Consequently, 
SEDDS are usually referred to as self-nanoemulsifying drug delivery systems 
(SNEDDS) or self-microemulsifying drug delivery systems (SMEDDS) depending on 
the nature of the resulting dispersions formed following their dilution [20].
SEDDS have been reported to enhance the oral bioavailability of poorly water-
soluble drugs particularly those belonging to class II of the Biopharmaceutics 
Classification System by multiple underlying mechanisms [22]. Among these 
mechanisms, the enhanced drug solubilization was the most widely investigated. 
Lipidic components of SEDDS stimulate lipoprotein/chylomicron production thus 
promoting drug absorption [23]. The ultrafine droplet size range of the resulting 
emulsion provides a large surface area of interaction with gastrointestinal (GI) 
membranes [24]. Importantly, the bioactive effects of various ingredients employed 
in SEDDS formulation have significantly contributed to the enhanced oral bioavail-
ability of the loaded drugs. These bioactive effects include tight junction opening 
and increasing membrane fluidity by the high surfactant content employed in 
SEDDS formulation [25]. Furthermore, stimulation of the intestinal lymphatic 
pathway as well as inhibition of intestinal drug efflux pumps such as P-glycoprotein 
(P-gp) and intestinal cytochrome P450 3A4 (CYP3A4) are considered promising 
strategies for enhancing the oral delivery of P-gp substrates and bypassing intesti-
nal and hepatic first pass metabolism [26].
P-gp is an energy-dependent membrane bound protein and the most abundantly 
distributed ATP-binding cassette transmembrane transporter throughout the body 
[27]. P-gp prevents the accumulation of endogenous substances and xenobiotics 
in cells by transporting them back to the extracellular space [28]. Unfortunately, 
intestinal P-gp transporters hamper the intestinal uptake of substrate drugs thus, 
reducing their oral bioavailability. Additionally, overexpression of P-gp transporters 
is involved in the development of multidrug resistance (MDR) in numerous human 
tumor types [29]. Hence, many strategies have been developed to inhibit P-gp 
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activity for enhancing the oral bioavailability of P-gp substrate drugs and revers-
ing MDR in tumor cells. Among these strategies, nanocarriers have been widely 
investigated [26]. Nanocarriers have the advantage of protecting P-gp substrates 
against premature release and interaction with the biological environment [30]. 
They control drug tissue distribution and favorably accumulate in tumor tissue  
[31, 32]. Among various nanocarriers, SEDDS have been widely explored to enhance 
the oral bioavailability of P-gp substrate drugs and reverse MDR in tumor cells.
Interestingly, the unique combination of SEDDS properties allows the enhance-
ment of oral bioavailability of both hydrophobic and hydrophilic drugs [33]. 
The oral delivery of protein therapeutics and genetic materials represents a real 
challenge due to their hydrophilic nature and their large molecular weight. In this 
chapter, we discuss the recent progress in the application of SEDDS for enhanc-
ing the oral bioavailability of P-gp substrates, reversing MDR in tumor cells and 
oral delivery of protein therapeutics and genetic materials. The aim of the current 
discussion is to call attention to the unique combination of SEDDS properties that 
makes them multifunctional delivery systems acting via various mechanisms to 
enhance the oral delivery of target therapeutic agents.
3.1 SEDDS overcome P-gp-mediated efflux and reverse MDR in tumor cells
Over the past 2 decades, SEDDS have been widely investigated to overcome 
P-gp-mediated efflux of substrate drugs to enhance their oral bioavailability. The 
potential of SEDDS to inhibit P-gp activity relies mainly on the excipients with 
established P-gp inhibition activity that are employed in the formulation [26]. 
Nonionic surfactants are the most widely employed excipients and are considered 
the mainstays of P-gp inhibition by SEDDS [29]. Cremophor EL, Cremophor RH40, 
vitamin E TPGS 1000, Labrasol, Transcutol P and Tween 80 are the most frequently 
employed. P-gp inhibition activity of a given surfactant depends on its HLB value 
and the structure of its hydrophobic domain [34]. There is no obvious correlation 
between surfactants’ HLB values and P-gp inhibition activity. Structurally, the 
hydrophobic moieties of the surfactant should be linked to polyoxyethylene hydro-
philic side chains to inhibit P-gp activity [34].
The binding affinity of nonionic surfactants to the hydrophobic portion of P-gp 
molecule is different from that of ionic surfactants [35]. Nonionic surfactants can 
change the secondary or tertiary structure of P-gp molecule resulting in the loss of 
its function [36]. Additionally, non-ionic surfactants were reported to modulate 
P-gp activity by inhibiting P-gp ATPase activity and either membrane fluidization 
or rigidization [37, 38]. At concentrations below the critical micelle concentration, 
nonionic surfactants are most effective in reducing P-gp activity; however, surfac-
tant micelles showed some P-gp modulation activity [26].
SEDDS have superior formulation efficiency and in vivo performance compared 
to their individual components [39]. Various formulation aspects of SEDDS can 
potentiate the P-gp inhibition activity of their ingredients. The entrapment of 
P-gp substrate within the ultrafine emulsion droplets provides a protection against 
recognition by P-gp efflux pumps at GI epithelium [33]. In addition, SEDDS allow 
the co-administration of several excipients which are co-localized in close proxim-
ity to GI epithelium [22]. Further, pharmaceutical excipients with established P-gp 
inhibition activity (e.g., curcumin) or traditional P-gp inhibitors (e.g., elacridar) 
could be loaded into the SEDDS formulation to further augment their P-gp inhibi-
tion activity [40, 41].
On the other hand, the efflux of chemotherapeutic agents by P-gp transport-
ers, which are overexpressed in tumor cells, represents a major obstacle in cancer 
chemotherapy [42]. SEDDS are extensively investigated to overcome MDR in tumor 
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cells which is partly attributed to the overexpression of P-gp efflux transporters. 
SEDDS allow the combinational delivery of multiple chemotherapeutic agents act-
ing via independent pathways in the same vector to produce a synergistic anticancer 
activity [42]. Interestingly, SEDDS could be employed for the co-delivery of various 
antioxidants for overcoming the oxidative stress in cancer cells [43].
3.2 SEDDS enhance the oral delivery of protein and peptide therapeutics
Protein therapeutics have a significant role in almost every field of medicine. 
However, the extensive application of protein therapeutics is challenged by their 
route of administration, being administered by parenteral route which is associated 
with reduced patient compliance [44]. Consequently, there is a great interest in the 
development of noninvasive strategies for delivery of protein therapeutics [45]. 
Oral delivery systems have been extensively investigated for the administration 
of protein drugs [46]. Unfortunately, the oral delivery of protein and/or peptide 
therapeutics is challenged by several barriers including the acidic environment 
Protein SEDDS composition Bioavailability 
increase
Control Animal 
species
Ref.
β-lactamase Lauroglycol FCC (41.7%)
Cremophor EL (33.3%)
Transcutol HP (25%)
1.29-fold β-lactamase 
solution
Sprague–
Dawley rats
[54]
Insulin Miglyol 840 (65%)
Cremophor EL (25%)
Co-solvent (DMSO and 
glycerol, 1:3) (10%)
3.33-fold Insulin solution Sprague–
Dawley rats
[55]
Insulin Ethyl oleate (35%)
Cremophor El (32.5%)
Alcohol (32.5%)
6.5-fold Insulin solution Male Wistar 
rats
[56]
Leuprorelin Capmul MCM (30%)
Cremophor EL (30%)
Propylene glycol (10%)
Captex 355 (30%)
17.2-fold Leuprolide 
acetate solution
Sprague-
Dawley rats
[57]
Pidotimod† Oil phase:
SoyPC (9.6%)
Span 80 (21.1%)
Oleic acid (36.1%)
MCT (12%)
0.5% gelatin solution (3%)
H2O (12%)
Surfactant phase:
Tween 80 (6%)
2.56-fold Pidotimod 
solution
Sprague–
Dawley rats
[48]
Enoxaparin Captex 8000 (30%)
Capmul MCM (30%)
Cremophor El (30%)
Propylene glycol (10%)
2.25%▪ Enoxaparin IV 
solution
Sprague-
Dawley rats
[58]
Labrafil 1944 (35%)
Capmul PG 8 (25%)
Cremophor EL (30%)
Propylene glycol (10%)
2.02%▪
Abbreviations: DMSO, dimethyl sulfoxide; MCT, medium chain triglycerides. 
▪Absolute bioavailability.
†Self -double emulsifying drug delivery system.
Table 1. 
SEDDS-mediated enhancement in the oral bioavailability of various proteins. Reprinted with permission from 
Ref. [33] © Elsevier (2018).
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Figure 1. 
A schematic representation of some underlying mechanisms for the enhanced oral bioavailability of protein 
therapeutics by SEDDS (HIPC, hydrophobic ion paired complex). Reprinted with permission from Ref. [33] © 
Elsevier (2018).
in the stomach, degradation by GI enzymes, mucus barrier as well as low cellular 
penetration [47]. Several strategies have been developed to overcome these bar-
riers [48–50]. As shown in Table 1, SEDDS have been extensively investigated as 
promising carriers for oral delivery of protein and peptide therapeutics. Various 
surfactants and oils that are employed in SEDDS formulation have a permeation 
enhancing effects; thus, they increase the cellular uptake of hydrophilic macromol-
ecules such as protein therapeutics. The ultrafine droplet size provides a large sur-
face area for rapid intestinal permeability. The anhydrous nature of SEDDS protects 
proteins against aqueous hydrolysis. Other bioactive effects of SEDDS such as tight 
junction opening, and enhanced lymphatic uptake also contribute to the enhanced 
oral bioavailability of loaded protein therapeutics [49]. However, loading of protein 
therapeutics into SEDDS is challenged by their hydrophilic nature. Thus, the lipid 
solubility of protein therapeutic should be increased before their incorporation into 
the SEDDS preconcentrate. This could be achieved by various techniques including, 
hydrophobic ion pairing [51], double emulsification [48], using hydrophilic solvents 
or co-solvents [52] and chemical modification of the peptide molecule [53].
Figure 1 summarizes various hypotheses for the enhanced oral delivery of 
protein and peptide therapeutics by SEDDS. Protein therapeutics incorporated 
within the ultrafine oil droplets are effectively protected against degradation by 
GI enzymes. Further, these cargoes are absorbed when the nanosized oil droplets 
are absorbed. Thus, the protection against enzymatic degradation is achieved via 
controlling the release rate of loaded protein therapeutic [59]. Burst release could 
result in rapid degradation of protein molecules within the GI lumen before reach-
ing the absorption site [60]. Another suggested mechanism for the enhanced oral 
bioavailability by protein therapeutics incorporated in SEDDS is based on the 
bioactive effects of SEDDS ingredients. They include mucus penetration, enhanced 
paracellular transport via opening of tight junction, and enhanced cellular uptake 
by transcytosis-mediated transcellular transport [61, 62]. Finally, enhancing the 
lipid solubility of protein molecules via hydrophobic ion pairing could increase 
their intestinal uptake and bioavailability. However, this hypothesis is challenged by 
the rapid dissociation of hydrophobic ion paired complexes within the GI fluids.
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3.3 SEDDS as promising vectors for oral delivery of genetic materials
Oral gene therapy allows the sustained production of therapeutic proteins 
locally at the disease site as well as for systemic absorption [63]. Unfortunately, 
the oral delivery of plasmid DNA (pDNA) as well as other nucleic acid products is 
challenged by their safe and efficient delivery as well as cellular internalization and 
processing [64]. SEDDS have been investigated as promising non-viral vectors for 
oral delivery of genetic materials. The superior cellular permeation and stability of 
pDNA loaded into SEDDS could be mainly attributed to its entrapment within the 
ultrafine nanoemulsion oil droplets.
3.4 Characterization of SEDDS
3.4.1 Stability of SEDDS preconcentrates
SEDDS preconcentrates should have sufficient stability to avoid drug precipita-
tion as well as creaming or phase separation of the resulting nano- or microemul-
sions. If some components of SEDDS preconcentrate undergo physical or chemical 
instability, the resulting emulsion may become unstable [20]. Thus, the stability of 
SEDDS preconcentrate should be evaluated by subjecting the nano- or microemul-
sion, resulting from aqueous dilution of the preconcentrate, to a centrifugation 
study at 5000 rpm for 30 min [65]. Then, SEDDS preconcentrates are subjected to 
heating–cooling cycle which includes six cycles of storage at 4 and 40°C for 48 h 
at each temperature followed by freeze–thaw cycle which involves three cycles of 
storage at −21 and 25°C for 48 h at each temperature [66].
3.4.2 Robustness to dilution
Robustness of the resulting emulsion to dilution guarantees the absence of drug 
precipitation when SEDDS preconcentrates are subjected to high dilution folds in 
vivo [21]. Thus, SEDDS preconcentrates should be exposed to different dilution 
folds (e.g., 50-, 100-, and 1000-folds) with different media (e.g., 0.1 N HCl and 
phosphate buffer, pH 6.8) to mimic in vivo conditions [20].
3.4.3 Assessment of self-emulsification efficiency
Self-emulsification efficiency is assessed by determining self-emulsification 
time and the efficiency of preconcentrate dispersibility when it is exposed to 
aqueous dilution. The SEDDS preconcentrate is added drop wise to aqueous media 
with different pH values and composition in a standard USP dissolution apparatus. 
Self-emulsification time is determined visually as the time required for the pre-
concentrate to form a homogenous dispersion [21]. The efficiency of preconcen-
trate dispersibility is also determined visually and is given in grades according to 
previously reported grading systems [20, 67, 68]. The selection of the appropriate 
grading system depends on the dilution fold to which the preconcentrate is exposed. 
This test ensures the ability of SEDDS preconcentrates to disperse quickly in order 
to form fine emulsions when they are exposed to aqueous media under mild agita-
tion provided by the GI peristaltic movement.
3.4.4 Cloud point measurement
Cloud point could be measured after 100-fold dilution of the preconcentrate 
with distilled water which is then placed in a water bath with gradual increase 
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Figure 2. 
Transmission electron microscope photograph shows spherical nanoemulsion droplets without any signs of 
aggregation. Reprinted with permission from Ref. [20]. © Elsevier (2017).
in temperature. Cloud point is determined as the temperature above which the 
emulsion clarity turns into cloudiness which is attributed to the dehydration of 
polyethylene oxide moiety of non-ionic surfactants [69]. Cloud point values should 
be sufficiently higher than 37°C (i.e., normal body temperature) to avoid phase 
separation in the GI tract [70].
3.4.5 Determination of zeta potential, mean droplet size and polydispersity index
Mean droplet size affects the in vivo performance of SEDDS. Small mean droplet 
size provides large interfacial area for drug absorption and ensures the kinetic 
stability of the resulting emulsion. Small value of polydispersity index suggests 
good uniformity of droplet size distribution. High zeta potential values confirm the 
electrical stability of emulsion droplets and absence of aggregation [66].
3.4.6 Droplet morphology
The morphology of emulsion droplets could be determined by transmission 
electron microscopy after appropriate dilution of SEDDS preconcentrate (about 
1000-fold) using 2% solution of either phosphotungstic acid or uranyl acetate for 
negative staining. Droplets should possess a spherical shape without any signs of 
aggregation or drug precipitation as shown in Figure 2.
3.4.7 In vitro lipolysis
Drugs incorporated into lipid-based formulations are already present in a dis-
solved form. Thus, the assessment of the applicability of these formulations should 
be more properly based on the rate of drug precipitation over time. On the other 
hand, the drug solubilization capacity of lipid-based formulations is not a function 
of formulation characteristics alone. Rather, formulation dispersion and digestion 
result in the formation of colloidal species that account for the intestinal solubiliza-
tion capacity [71]. Consequently, possible changes to solubilization capacity that 
could be attributed to digestion of formulation ingredients or interaction with 
biliary solubilizing agents should be assessed. In vitro lipolysis models simulate the 
GI environment and better predict the in vivo behavior of lipid-based formulations 
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such as SEDDS. They also assess the extent of drug precipitation as a result of diges-
tion of formulation ingredients and changes to solubilization capacity [72].
4. Solid self-emulsifying drug delivery systems
It was reported that ~70% of newly discovered drug molecules and ~ 40% of 
marketed drugs for oral administration are classified as practically insoluble in water. 
Therefore, various strategies have been explored to enhance the aqueous solubility and 
thus oral bioavailability of these drugs. SEDDS have been investigated as an efficient 
strategy that allows drug administration in pre-solubilized form ready for absorption. 
Consequently, drugs loaded into SEDDS preconcentrates avoid the dissolution step 
that frequently limits their absorption. However, the widespread application of liquid 
SEDDS is challenged by low stability during handling or storage [73] and irrevers-
ible drug and/or excipient precipitation [74]. Thus, the majority of marketed liquid 
SEDDS are filled into soft gelatin (e.g., SandimunneNeoral®, Norvir®, Fortovase®, and 
Convulex®) or hard gelatin capsules (e.g., Gengraf® and Lipirex®) to be administered 
as a unit dosage form [75]. However, this approach still possesses the possibility of drug 
precipitation upon exposure to aqueous media. Additionally, capsule technologies 
have some limitations such as high production cost and the risk of interaction between 
the active pharmaceutical ingredient and excipients with the capsule shell. Also, the 
possibility of drug leakage out of the capsule shell and capsule aging represent further 
obstacles [76]. Further, the storage temperature is an important consideration since 
the drug and/or excipients could undergo precipitation at lower temperatures [75]. 
The tendency of volatile excipients to evaporate into the capsule shell results in drug 
precipitation and a consequent alteration of drug release [77].
Thus, to address these limitations solid self-emulsifying drug delivery systems 
(s-SEDDS) were developed by converting the conventional liquid SEDDS into 
powders which are subsequently filled into capsules or formulated as solid dos-
age forms such as self-emulsifying tablets, granules, pellets, beads, microspheres, 
nanoparticles, suppositories and implants [74, 78]. Various solidification techniques 
for converting liquid SEDDS into s-SEDDS are discussed below.
4.1  Solidification techniques for converting liquid or semisolid SEDDS to 
s-SEDDS
4.1.1 Adsorption to solid carriers
Adsorption to highly porous and/or high specific area solid carriers is the most 
intensively explored approach to obtain s-SEDDS [75]. This technique could be 
effectively used to produce s-SEDDS by simple mixing of solid carriers with the 
liquid formulation in a blender [74]. The most frequently employed carriers for 
adsorption of liquid SEDDS formulations are: (i) silicon dioxide such as Aerosil® 
(fumed silica) and Sylysia® (micronized amorphous silica); (ii) Neusilin® (mag-
nesium aluminometasilicate) which is available in different surface properties and 
particle size; (iii) Fujicalin® (porous dibasic calcium phosphate anhydrous) and 
(iv) calcium silicate [75].
Advantages of this solidification technique include:( i) good content uniformity 
of the produced powders [79]; (ii) high drug loading efficiency (up to 80% w/w 
without affecting flow properties) [80]; (iii) absence of organic solvents [81];  
(iv) cost effectiveness because small number of excipients and basic equipment are 
required for the final formulation and (v) production of free-flowing powders that 
can be filled into capsule or compressed into other solid dosage form [82].
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During the formulation of s-SEDDS by adsorption technique, careful consideration 
should be given to the possible interactions between the solid carrier and the drug or 
other excipients in liquid SEDDS which could result in delayed or incomplete release 
of loaded drug [83]. Additionally, the particle size, specific surface area, tortuosity of 
pores as well as type and liquid SEDDS: carrier ratio should be considered [75].
4.1.2 Spray drying
Spray drying is also a promising technique for transforming liquid SEDDS to 
s-SEDDS using different carriers (i.e., hydrophobic or hydrophilic carriers) which 
preserve the self-emulsifying properties of the formulation. It is a simple and eco-
nomical technique which involves mixing of lipids, surfactants, drug and solid carri-
ers followed by solubilization and spray drying. The solubilized mixture is atomized 
into a spray of fine droplets that are introduced into a drying chamber where the 
volatile phase evaporates forming dry particles under controlled conditions of tem-
perature and airflow [74]. The type of carrier can affect the rate of release and thus 
the oral bioavailability of loaded drug by affecting the droplet size of the nano or 
microemulsion formed after reconstitution [84]. Also, careful consideration should 
be given to the atomizer, the airflow pattern, the temperature and the design of the 
drying chamber which should be selected according to the powder specifications. 
Low yield is a disadvantage of solidification by spray drying technique which could 
be attributed to the removal of non-encapsulated drug with the exhausted air [85].
4.1.3 Extrusion/spheronization
Extrusion/spheronization is the most explored technique for the production of 
uniformly sized self-emulsifying pellets [75]. Extrusion is a procedure of converting 
a raw material with plastic properties into a spaghetti-shaped agglomerate having 
uniform density. Extrusion is followed by spheronization where the extrudate is 
broken into spherical pellets (spheroids) of uniform size [86]. The produced pellets 
have good flowability and low friability. Before pellet production, the wet mass is 
composed of liquid SEDDS, lactose, microcrystalline cellulose (MCC) and water. 
A disintegrating agent could be added to enhance drug release [87]. MCC acts as 
adsorbent for the liquid SEDDS to ease pellet formation and avoid problems such 
as poor flow properties, pellet agglomeration and low hardness. Larger amount of 
liquid SEDDS can be loaded into the pellets when a greater quantity of MCC on the 
account of lower amount of lactose is employed in the formulation. The ratio of 
lactose: MCC and liquid SEDDS: water affects the pellets’ disintegration time and 
surface roughness as well as the extrusion force [88].
4.1.4 Microencapsulation
Co-extrusion technique is a promising strategy for microencapsulation of liquid 
SEDDS into polymeric matrices. This technique employs a vibrating nozzle device 
equipped with a concentric nozzle. The formed microcapsules are then hardened 
by ionotropic gelation. Ionotropic gelation is based on the gel formation ability of 
polysaccharides (e.g., pectin, alginate, carrageenan, and gellan) in the presence 
of multivalent ions (e.g., Ca+2) [89]. Alginate and pectin are the most intensively 
investigated natural ionic polysaccharides for formation of microcapsule shell. 
However, Ca-alginate microcapsules clog the nozzle during the microencapsulation 
process. On the other hand, pectin microcapsules lack sufficient hardness. Thus, 
microcapsules composed of an alginate-pectin matrix could be more acceptable 
than those composed solely of one polymer. Various hydrophilic filling agents  
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(e.g., lactose) could be added to the shell formation phase in order to prevent core 
leakage and microcapsule collapse during the drying process. Advantages of micro-
capsules include predictable GI transit time and large surface area that allow faster 
drug dissolution. Additionally, they are composed of biocompatible, non-toxic and 
biodegradable natural polymers [90].
4.1.5 Wet granulation
Different carriers (e.g., Aerosil® 200) were employed to prepare the self-emulsifying 
granules where the liquid SEDDS acts as a binder. However, granulation with SEDDS 
produces a broader size distribution and difficult to control aggregation compared with 
granulation procedure where water is employed as granulating agent [91].
4.1.6 Melt granulation
In this process, powder agglomeration is attained by the addition of binding 
agent which melts at relatively low temperature such as Gelucire®, lecithin, partial 
glycerides or polysorbates [92]. While the liquid SEDDS is adsorbed to neutral 
carriers such as silica and magnesium aluminometasilicate [93]. Melt granulation is 
advantageous compared to wet granulation since it is a ‘one-step’ process in which 
the addition of granulating liquid and the following drying phase are absent [74].
4.2 Characterization of s-SEDDS
SEDDS are combinations of SEDDS and solid dosage forms. Therefore, the 
characterization of s-SEDDS is the sum of the corresponding evaluation criteria of 
both SEDDS and solid dosage forms.
4.2.1 Solid state characterization
4.2.1.1 Differential scanning calorimetry (DSC)
DSC is mainly employed to ensure drug incorporation into the s-SEDDS as well 
as the absence of drug-solid carrier interaction. It is also used to investigate the 
physical state (i.e., crystalline or amorphous) of the incorporated drug in the final 
formulation [94]. Transition from the crystalline to amorphous state is common in 
SEDDS formulations which lowers the drug melting point and improves its solubil-
ity and dissolution rate [95].
4.2.1.2 X-ray diffractometry (XRD)
XRD is employed to investigate the physical state of the incorporated drug 
because it affects both in vitro and in vivo performance.
4.2.1.3 Scanning electron microscopy (SEM)
SEM is employed to elucidate the structural and morphological features of s-SEDDS 
and the raw materials as well as to confirm the physical state of loaded drug [96].
4.2.1.4 Fourier-transform infrared spectroscopy (FT-IR)
FT-IR is usually employed to investigate any potential interaction between the 
incorporated drug and the solid carrier or other formulation excipients [76].
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4.2.2 Determination of micromeritic properties
The flow properties of powders are crucial aspect of large-scale production of 
solid dosage forms because it affects feeding consistency, reproducibility of die filling 
and dose uniformity. Powder flowability is affected by various physical, mechanical 
and environmental factors. Thus, various parameters such as angle of repose, bulk 
density, Carr’s index and Hausner’s ratio should be assessed to determine s-SEDDS 
flowability to overcome the subjective nature of individual tests. The angle of repose 
is a measure of internal cohesiveness of particles. Powders having angles of repose 
<30° are considered as free flowing powders; while, powders with angles of  
repose >40° are regarded to have extremely poor flowability. On the other hand, 
powders with angles of repose up to 35° are regarded passable; while, those between 
35 and 40° indicate poor powder flow which requires the addition of a glidant [97]. 
Powders having Carr’s index up to 21% are considered to have acceptable flow. 
Hausner’s ratios <1.25 are usually corresponded to free-flowing powders with mini-
mum interparticle frictions. On the other hand, Hausner’s ratios between 1.25 and 1.5 
indicate moderate flow which could be acceptable [98].
4.2.3 Droplet size of reconstituted s-SEDDS
The droplet size of reconstituted s-SEDDS should be similar to that of liquid SEDDS 
to ensure that the self-emulsification performance of liquid SEDDS is preserved.
5. Conclusion
SEDDS are promising nanocarriers for overcoming various obstacles encoun-
tered in the oral delivery of drugs and bioactive agents. The inhibition of P-gp 
activity by SEDDS relies mainly on the employment of ingredients (i.e., oils and 
surfactants) with established P-gp inhibition activity in their formulation. Thus, 
selection of excipients with established P-gp inhibition activity is the first step in 
the formulation of SEDDS for overcoming P-gp-mediated efflux of substrate drugs 
and reversing MDR in tumor cells. The effective concentration range for inhibit-
ing P-gp activity should be considered while selecting the formulation ratios. P-gp 
inhibition activity of SEDDS can be further enhanced by loading other pharmaceu-
tical excipient with established P-gp inhibition activity or traditional P-gp inhibitor. 
SEDDS are also considered promising systems for the oral delivery of protein thera-
peutics and genetic materials; however, this role is still in its infancy. Entrapment of 
these macromolecules within the nanosized emulsion droplets guarantees effective 
delivery. The bioactive effects of SEDDS ingredients could further enhance the oral 
bioavailability of protein therapeutics. Liquid SEDDS could be transformed into 
s-SEDDS to further enhance the formulation stability, allow cost effective large-
scale production as well as to enhance the patient compliance.
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